Startseite>>Signaling Pathways>> Microbiology & Virology>> SARS-CoV>>Merafloxacin

Merafloxacin (Synonyms: CI-934)

Katalog-Nr.GC63065

Merafloxacin (CI-934), ein Fluorchinolon-Antibiotikum, ist ein selektiver programmierter -1 ribosomaler Frameshifting (-1 PRF)-Inhibitor von Beta-Coronaviren.

Products are for research use only. Not for human use. We do not sell to patients.

Merafloxacin Chemische Struktur

Cas No.: 91188-00-0

Größe Preis Lagerbestand Menge
5 mg
135,00 $
Auf Lager
10 mg
225,00 $
Auf Lager
25 mg
450,00 $
Auf Lager
50 mg
702,00 $
Auf Lager
100 mg
1.035,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Merafloxacin (CI-934), a fluoroquinolone antibacterial agent, is a selective programmed -1 ribosomal frameshifting (-1 PRF) inhibitor of beta coronaviruses. Merafloxacin exhibits in vitro activity against gram-positive and gram-negative bacteria[1][2].

Merafloxacin (5-80 μM) dose-dependently inhibits programmed -1 ribosomal frameshifting (-1 PRF) of SARS-CoV-2, SARS-CoV, hCoVO-C43, and hCoV-HKU1, with IC50s of 19.6 μM, 19.5 μM, 29.7 μM, and 38.6 μM, respectively[1].

[1]. Sun Y, et, al. Restriction of SARS-CoV-2 Replication by Targeting Programmed -1 Ribosomal Frameshifting In Vitro. bioRxiv. 2020 Oct 21;2020.10.21.349225.
[2]. Mandell W, et, al. In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents. Antimicrob Agents Chemother. 1986 May;29(5):852-7.

Bewertungen

Review for Merafloxacin

Average Rating: 5 ★★★★★ (Based on Reviews and 17 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Merafloxacin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.